
Letermovir 240 mg (Anvimo 240) is an antiviral medicine used to prevent cytomegalovirus (CMV) infection and disease in certain high-risk patients, particularly those who have undergone stem cell or kidney transplantation. It contains Letermovir, which targets a specific protein complex required for CMV viral replication. By interfering with the virus’s ability to reproduce, it helps reduce the risk of CMV-related complications during recovery after transplantation.
| Generic Name | Letermovir |
| Manufacturer | Zydus |
| Packing | 30 Tablets |
| Prescribed For | Prevent cytomegalovirus (CMV) infection and disease in high-risk transplant recipients |
| Availability | In Stock |
| Shipping to | USA, UK, Australia, Canada, New Zealand, Philippines, Tunisia, France, Italy, South Korea, Albania, Romania, Hong Kong, Malaysia, Thailand, Singapore, Japan, UAE, Saudi Arabia, Qatar, Kuwait, Georgia, Mexico, and many other countries. |




Letermovir works by blocking the cytomegalovirus (CMV) terminase complex, particularly the pUL56 protein. This complex plays an important role in processing and packaging viral DNA into new virus particles. By interfering with this process, Letermovir prevents the formation of infectious CMV particles and helps control the risk of viral infection.